• Illumina Launches Genomics Accelerator

    Xconomy | Illumina is creating a genomics-focused accelerator at its Mission Bay R&D facility under construction in San Francisco.

    Feb 13, 2014

  • GenomOncology Announces Collaborations, Partnerships Before AGBT

    Bio-IT World | GenomOncology has announced several collaborations and partnerships surrounding its step-by-step workflow that takes raw data from the sequencer and translates the molecular profile of each patient’s tumor genome into an actionable clinical report. Recent partnerships include Roswell Park Cancer Institute, Vanderbilt-Ingram Cancer Center, University of Pittsburgh, and CompanionDx.

    Feb 12, 2014

  • QuantuMDx Launches MolDx Indiegogo Campaign

    Bio-IT World | QuantuMDx is taking their handheld molecular diagnostic tool to the masses, and hoping to raise $50,000 in an Indiegogo campaign starting today. The money will support a malaria clinical trial in Africa. 

    Feb 12, 2014

  • AWS to Offer Enterprise R Package

    Computerworld | Amazon Web Services is now hosting R and offering it to users to run on AWS using the commercial package of R--Revolution R Enterprise 7.

    Feb 11, 2014

  • Bina Pushes Toward Clinic with New SAB Members

    Bio-IT World | Bina Technologies has announced an expanded Scientific Advisory Board including three new clinical genomicists and a bioinformatician. The additions herald an increased interest in clinical genomics space.

    Feb 10, 2014

  • A Crisper Image of Cas9 Structure

    Bio-IT World News Brief | A new study of the Cas9 protein, used in both natural and artificial CRISPR gene editing complexes, reveals its crystal structure and new information on its partnership with gRNA to target specific DNA sequences for cleaving.

    Feb 7, 2014

  • Stanford Hospitals Open Clinical Genomics Service

    Bio-IT World News Brief | Two hospitals associated with the Stanford School of Medicine today announced the opening of a new Clinical Genomics Service, becoming the latest clinical centers to use broad genome sequencing to make difficult diagnoses.

    Feb 6, 2014

  • New Industry Report on Prenatal Diagnostics

    Bio-IT World | A new report from the Insight Pharma Reports series highlights the changing landscape of prenatal diagnostics, featuring interviews with executives from leading companies in the field.

    Feb 6, 2014

  • Natera NIPT to Expand Into Microdeletions

    Business Wire | Natera announced today that the company's Panorama non-invasive prenatal test will soon cover conditions like DiGeorge syndrome, which are caused by small deletions along the length of the chromosome.

    Feb 5, 2014

  • Deanna Church Brings Reference Genome Expertise to Personalis

    Bio-IT World | Deanna Church, longtime leader of the NCBI contributions to the Genome Reference Consortium, has joined Stanford-area startup Personalis offering genome interpretation and genetic diagnostics. Bio-IT World spoke with her about her new role using the human reference genome that she has contributed so much to.

    Feb 5, 2014

  • Illumina Speaks About Plans for Clinical Sequencing

    Clinical Informatics News | Illumina will use 2014 to continue development of new diagnostic applications for the MiSeqDx, including in the oncology space, and to submit the HiSeq 2500 for FDA approval.

    Feb 4, 2014

  • Thermo Fisher Closes Life Technologies Buy

    Bio-IT World News Brief | Thermo Fisher Scientific announced yesterday that it has finally completed its acquisition of Life Technologies, following months of preparation and negotiations with both the FTC and European Commission to approve the purchase.

    Feb 4, 2014

  • Dicerna IPO Proves Investor Interest in RNAi

    Boston Globe | Dicerna Pharmaceuticals, a Watertown-based company developing RNA interference therapies, showed the largest first-day gains in share price for any company since 2005 when it went public on Thursday.

    Feb 3, 2014

  • January News and Product Briefs

    Bio-IT World | News and product releases from around the industry, including a collaboration for multiple sclerosis drug discovery, and new platforms for integrating NGS workflows and mimicking liver enzyme metabolism.

    Feb 3, 2014

  • Accelrys CEO on Dassault Acquisition

    Bio-IT World | Yesterday, Dassault Systèmes, a Paris-based company focused on Product Lifecycle Management (PLM), announced its intention to acquire Accelrys for approximately $750 million. Max Carnecchia, CEO of Accelrys, spoke with Bio-IT World this afternoon to give the announcement some context. 

    Jan 31, 2014

  • Johnson & Johnson Announces New Model for Data Transparency

    Xconomy | Johnson & Johnson today announced that an independent group at Yale will be empowered to review and grant scientific requests to see the full results of any clinical trial in the company's records.

    Jan 30, 2014

  • GenePeeks Readies Its In Silico Nursery

    Bio-IT World | GenePeeks, preparing to launch its service minimizing the risk of genetic disorders in children conceived through sperm donors, is awarded a patent for algorithms that create "digital children" from parental genotypes.

    Jan 30, 2014

  • Accelrys Acquired by Dassault Systemes for $750m

    Bio-IT World News Brief | Dassault Systèmes, a French company focused on Product Lifecycle Management (PLM), 3D design software and 3D digital Mock Up, announced its definitive agreement to acquire Accelrys last night in an all cash tender offer, representing a fully diluted equity value for Accelrys of approximately $750 million.

    Jan 30, 2014

  • Gene Therapy's Next Generation

    Bio-IT World | As a new generation of gene editing technologies like CRISPR and TALEN emerges, the founders of Editas Medicine think the time is right to forge ahead with gene therapy.

    Jan 29, 2014

  • Plotting the Discovery Curve: 33 New Cancer-Causing Mutations

    Bio-IT World | In a paper published in Nature last week, Broad researchers identified 33 new point mutations associated with cancer and estimated that mutations associated with at least 10% of cancer cases have been IDd. The next step is to find those mutations involved in only 5% or 2% of cancers.

    Jan 28, 2014